NO20062031L - Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media - Google Patents

Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media

Info

Publication number
NO20062031L
NO20062031L NO20062031A NO20062031A NO20062031L NO 20062031 L NO20062031 L NO 20062031L NO 20062031 A NO20062031 A NO 20062031A NO 20062031 A NO20062031 A NO 20062031A NO 20062031 L NO20062031 L NO 20062031L
Authority
NO
Norway
Prior art keywords
group
cycloalkyl
alkyl
phenyl
hydrogen atom
Prior art date
Application number
NO20062031A
Other languages
English (en)
Inventor
Gihad Dargazanli
Genevieve Estenne-Bouhtou
Corinne Veronique
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20062031L publication Critical patent/NO20062031L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det er beskrevet forbindelse som har generell formel (I), hvori: RI betyr et hydrogenatom, en alkylgruppe, en sykloalkylgruppe, en sykloalkyl alkylgruppe, en fenyl alkylgruppe, en alkenylgruppe eller en alkynylgruppe; R2 betyr en alkylgruppe, en sykloalkylgruppe eller en sykloalkyl alkylgruppe; X betyr et hydrogenatom eller et eller flere hallogenatomer og/eller trifluormetyl, alkyl eller alkoksygruppe; R3 betyr et hydrogenatom, eller et eller flere halogene atomer og/eller trifluormetyl, alkyl, sykloalkyl, alkoksy, fenyl, cyano, acetyl, benzoyl, tioalkyl, alkylsulfonyl, karboksy eller alkoksykarbonyl, eller en gruppe som har formelen NR4R5 eller S02NR4R5, hvori R4 og R5 betyr et hydrogenatom eller en alkyl eller sykloalkylgruppe eller NR4R5 betyr enpyrrolidin, piperiodin eller morfolin ring. Det er også beskrevet anvendelse av nevnte forbindelse i terapeutiske midler.
NO20062031A 2003-10-17 2006-05-05 Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media NO20062031L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312141A FR2861071B1 (fr) 2003-10-17 2003-10-17 Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
PCT/FR2004/002642 WO2005037782A2 (fr) 2003-10-17 2004-10-15 Derives de n-[phenyl(alkylpiperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
NO20062031L true NO20062031L (no) 2006-07-06

Family

ID=34385234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062031A NO20062031L (no) 2003-10-17 2006-05-05 Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media

Country Status (26)

Country Link
US (1) US7790753B2 (no)
EP (1) EP1682503B1 (no)
JP (1) JP4754494B2 (no)
CN (1) CN1882541B (no)
AT (1) ATE359268T1 (no)
AU (1) AU2004281216B2 (no)
BR (1) BRPI0415433A (no)
CA (1) CA2542925A1 (no)
CY (1) CY1106653T1 (no)
DE (1) DE602004005886T2 (no)
DK (1) DK1682503T3 (no)
ES (1) ES2282916T3 (no)
FR (1) FR2861071B1 (no)
HR (1) HRP20070203T3 (no)
IL (1) IL174936A (no)
MA (1) MA28100A1 (no)
ME (1) MEP12708A (no)
NO (1) NO20062031L (no)
NZ (1) NZ547166A (no)
PL (1) PL1682503T3 (no)
PT (1) PT1682503E (no)
RS (1) RS20060317A (no)
RU (1) RU2351589C2 (no)
SI (1) SI1682503T1 (no)
WO (1) WO2005037782A2 (no)
ZA (1) ZA200603942B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
GB0600427D0 (en) 2006-01-10 2006-02-15 Glaxo Group Ltd Compounds
EP2001831A2 (en) * 2006-04-05 2008-12-17 Glaxo Group Limited Compounds which inhibit the glycine transporter and uses thereof
GB0612416D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
JP2010523476A (ja) 2007-03-08 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ミトコンドリアアルデヒドデヒドロゲナーゼ−2モジュレーター及びその使用方法
TW200911808A (en) * 2007-07-23 2009-03-16 Astrazeneca Ab Novel compounds
WO2009024611A2 (en) 2007-08-22 2009-02-26 Abbott Gmbh & Co. Kg 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
MA32947B1 (fr) * 2009-01-27 2012-01-02 Hoffmann La Roche Piperidines substitues par aroylamino et heteroaroylamino comme inhibiteurs de glyt-1
AR075182A1 (es) * 2009-01-28 2011-03-16 Astrazeneca Ab Compuestos 2-aza-biciclo (2.2.2) octano y sus usos
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
MX2011009677A (es) * 2009-03-16 2011-09-30 Sanofi Sa Derivados de n-[(2-aza-biciclo[2.1.1]hex-1-il)-aril-metil]-heterob enzamida, su preparacion y su aplicacion en terapeutica.
FR2943056A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
JP5618047B2 (ja) * 2010-01-29 2014-11-05 国立大学法人千葉大学 ポジトロン断層撮影法およびポジトロン放出化合物
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2853254A1 (en) 2011-11-18 2013-05-23 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
CN105992764A (zh) 2013-10-17 2016-10-05 艾伯维德国有限责任两合公司 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物,包含其的药物组合物及其在治疗中的用途
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3801636A (en) * 1971-08-13 1974-04-02 Abbott Lab 3,4,5-tri-substituted cinnamides
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
JP3026845B2 (ja) 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
CZ284456B6 (cs) 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
KR20010032967A (ko) * 1998-03-06 2001-04-25 디르크 반테 글리신 수송 저해제
FR2838739B1 (fr) * 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
FR2842804B1 (fr) * 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
BR0316747A (pt) * 2002-12-18 2005-10-18 Fmc Corp Piperidinas n-(arilmetil substituìdas)-4-(metil dissubstituìdas) e piperazinas
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
WO2006110724A2 (en) * 2005-04-11 2006-10-19 Yale University Method of treating schizophrenia prodrome

Also Published As

Publication number Publication date
RU2006116886A (ru) 2007-11-27
MA28100A1 (fr) 2006-08-01
RU2351589C2 (ru) 2009-04-10
CN1882541A (zh) 2006-12-20
ATE359268T1 (de) 2007-05-15
DE602004005886T2 (de) 2008-01-17
CN1882541B (zh) 2011-07-06
JP2007508360A (ja) 2007-04-05
US20060223861A1 (en) 2006-10-05
DE602004005886D1 (de) 2007-05-24
AU2004281216A1 (en) 2005-04-28
PT1682503E (pt) 2007-05-31
CA2542925A1 (fr) 2005-04-28
WO2005037782A2 (fr) 2005-04-28
IL174936A0 (en) 2006-08-20
US7790753B2 (en) 2010-09-07
PL1682503T3 (pl) 2008-01-31
CY1106653T1 (el) 2012-01-25
HRP20070203T3 (en) 2007-06-30
EP1682503A2 (fr) 2006-07-26
FR2861071B1 (fr) 2006-01-06
MEP12708A (en) 2010-06-10
AU2004281216B2 (en) 2010-07-22
ES2282916T3 (es) 2007-10-16
ZA200603942B (en) 2007-11-28
WO2005037782A3 (fr) 2005-07-07
JP4754494B2 (ja) 2011-08-24
SI1682503T1 (sl) 2007-08-31
RS20060317A (en) 2008-11-28
FR2861071A1 (fr) 2005-04-22
IL174936A (en) 2011-01-31
NZ547166A (en) 2009-11-27
EP1682503B1 (fr) 2007-04-11
DK1682503T3 (da) 2007-07-16
BRPI0415433A (pt) 2006-12-05

Similar Documents

Publication Publication Date Title
NO20062031L (no) Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media
NO20062032L (no) Derivater av N-[fenyl(pyrrolidin-2-yl)-metyl]benzamid og N-[(azepan-2-yl)fenylmetyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske midler
WO2004013101A3 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
ES2193990T3 (es) Derivados de purina.
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
WO2004013100A3 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
RS54607B1 (en) 5-SUBSTITUATED HINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS
NO20030471L (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
HK1073659A1 (en) Arylsulphonamide derivatives and use thereof as b1 bradykinin receptor antagonists
NO20072053L (no) Nye bis-azaindolderivater, fremstilling og farmasoytisk anvendelse derav som kinaseinhibitorer
ATE491691T1 (de) Disubstituierte pyrazolylcarboxanilide
NO20054195D0 (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
NO20055977L (no) Nye benzimidazolderivater
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
DK1008592T3 (da) Cykliske amidderivater, som inhiberer cathepsin K
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
DE69231445T2 (de) Triazole enthaltende antifungizide mittel
DK0751944T3 (da) Thiazolidiner og oxazolidiner, der er substitueret med en pyridinring, og deres anvendelse som hypoglykæmiske midler
NO20065873L (no) 3-(4-(2-dihydroisoksazol-3-ylpyridin-5-yl)fenyl)-5-triazol-1-ylmetyloksoazolidin-2-on derivater som MAO inhibitorer i behandlingen av bakterielle infeksjoner
NO20065902L (no) 3-{4-(pyridin-3-yl)fenyl}-5-(1H-,1,2,3-triazol-1-ylmetyl)-1,3-oksazolidin-2-oner som antibakterielle midler
HRP20080173T3 (en) IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF mGluR5 RECEPTOR MEDIATED DISORDERS
TW200505446A (en) Inhibitor of cox

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application